Bayer partners with McMaster University

Alok Kanti (President, Bayer Inc. & Senior Bayer Representative) speaks at a luncheon at McMaster University in Hamilton, Ontario, to recognize the new chair.

Bayer Canada partnered with McMaster University to establish a Bayer Chair for Clinical Epidemiology Research in Bleeding Disorders at the university.

Dr. Alfonso Iorio has been named the inaugural holder of the new research position, effective June 2018. He is a professor and researcher of the Department of Health Research Methods, Evidence, and Impact and the Department of Medicine at McMaster University. He is also a clinician specializing in bleeding disorders for Hamilton Health Sciences.

“I am very excited about being named the inaugural chair recipient because I love this research field,” said Iorio. “I have spent more than 20 years of my career applying the principles of clinical epidemiology to research in bleeding disorders, so having the opportunity to focus on it further is rewarding.”

The Bayer Chair for Clinical Epidemiology Research in Bleeding Disorders, McMaster University, Hamilton, Ontario, is a new position responsible for contributing to the advancement of evidence‐based care for bleeding disorders by generating, summarizing and disseminating research results of the highest quality. This includes optimizing current and emerging treatments for hemophilia. The Chair is also responsible for undertaking educational roles to foster evidence-based care for bleeding disorders such as hemophilia.

Hemophilia, as defined by the Canadian Hemophilia Society, is a hereditary condition, in which the blood of a person does not clot normally. A person with hemophilia does not bleed more profusely or more quickly than other people; however, bleed for a longer time. External wounds are usually not serious. Far more important is internal bleeding (hemorrhaging) in joints, especially knees, ankles and elbows, and in tissues and muscles. When bleeding occurs in a vital organ, especially the brain, a hemophiliac's life is in danger. Both hemophilia A and B are very rare disorders. Hemophilia A affects fewer than 1 in 10,000 people, or about 2500 Canadians. Hemophilia B is even less common, affecting approximately 1 in 50,000 people, or about 600 Canadians.

Dr. Iorio will continue to make contributions in the area of bleeding disorders through research, teaching and clinical work. Bayer recognizes that in five to 10 years, breakthrough technologies like gene therapy and gene editing could enter the treatment landscape. This is why Dr. Iorio’s work to make clinical is so critical, and why this Chair is both timely and warranted.

"Bayer is honoured to support the Bayer Chair for Clinical Epidemiology Research and Bleeding Disorders," said Alok Kanti, President, Bayer Inc. & Senior Bayer Representative. "We are also dedicated to improving the quality of life for patients and increasing the body of scientific evidence in the field of bleeding disorders, which has been one of Dr. Iorio's passions, and a strength at McMaster University."